Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trial

PURPOSE: Benefit from convalescent plasma therapy for coronavirus disease 2019 (COVID-19) has been inconsistent in randomized clinical trials (RCTs) involving critically ill patients. As COVID-19 patients are immunologically heterogeneous, we hypothesized that immunologically similar COVID-19 subphe...

Descripción completa

Detalles Bibliográficos
Autores principales: Fish, M., Rynne, J., Jennings, A., Lam, C., Lamikanra, A. A., Ratcliff, J., Cellone-Trevelin, S., Timms, E., Jiriha, J., Tosi, I., Pramanik, R., Simmonds, P., Seth, S., Williams, J., Gordon, A. C., Knight, J., Smith, D. J., Whalley, J., Harrison, D., Rowan, K., Harvala, H., Klenerman, P., Estcourt, L., Menon, D. K., Roberts, D., Shankar-Hari, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472738/
https://www.ncbi.nlm.nih.gov/pubmed/36102943
http://dx.doi.org/10.1007/s00134-022-06869-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472738/
https://www.ncbi.nlm.nih.gov/pubmed/36102943
http://dx.doi.org/10.1007/s00134-022-06869-w

Ejemplares similares